Hemoglobinopathy clinical trials
12 active trials name this condition. Describe your situation to see which ones you may be eligible for.
By location
- Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- Expanded Access Protocol Using CD3+/CD19+ Depleted PBSC
- Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
- Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
- Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
- Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
- Long Term Follow-Up Study for Individuals With Hemoglobin Disorders After Hematopoietic Cell Transplant or Gene Therapy
- Study of the Role of Genetic Modifiers in Hemoglobinopathies
- Discarded Bone Marrow for Hematology Research
- Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling
- Allo HSCT for High Risk Hemoglobinopathies
- Naive T Cell Deplete Grafts for GVHD Prevention in Non-Malignant Diseases
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Hemoglobinopathy” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.